glp-1/gip agonist GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal Frontiers | Clinical perspectives on
Description
Assigned to tackle these questions, Drucker made a profound discovery: different organs processed proglucagonwell, differently
Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimers disease
PD clinical trials The neuroprotective effects of GLP-1RAs, particularly exenatide, seem to be more promising in PD
Scientists see possible links, but the evidence is still far from definitive This is a human-written story voiced by AI
